Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 820934, 8 pages
http://dx.doi.org/10.1155/2015/820934
Review Article

Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia

Division of Human Nutrition, Department of Agricultural, Food and Nutritional Science, University of Alberta, 4-002 Li Ka Shing Centre for Health Research Innovation, Edmonton, AB, Canada T6G 2E1

Received 15 January 2015; Revised 17 April 2015; Accepted 18 April 2015

Academic Editor: Alessandro Laviano

Copyright © 2015 Maryam Ebadi and Vera C. Mazurak. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Tisdale, “Cachexia in cancer patients,” Nature Reviews Cancer, vol. 2, no. 11, pp. 862–871, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Fearon, F. Strasser, S. D. Anker et al., “Definition and classification of cancer cachexia: an international consensus,” The Lancet Oncology, vol. 12, no. 5, pp. 489–495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Ebadi and V. C. Mazurak, “Evidence and mechanisms of fat depletion in cancer,” Nutrients, vol. 6, pp. 5280–5297, 2014. View at Google Scholar
  4. M. Rydén, T. Agustsson, J. Laurencikiene et al., “Lipolysis—not inflammation, cell death, or lipogenesis—is involved in adipose tissue loss in cancer cachexia,” Cancer, vol. 113, no. 7, pp. 1695–1704, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Agustsson, M. Rydén, J. Hoffstedt et al., “Mechanism of increased lipolysis in cancer cachexia,” Cancer Research, vol. 67, no. 11, pp. 5531–5537, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. Murphy, M. S. Wilke, M. Perrine et al., “Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients,” Clinical Nutrition, vol. 29, no. 4, pp. 482–487, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Fouladiun, U. Körner, I. Bosaeus, P. Daneryd, A. Hyltander, and K. G. Lundholm, “Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—correlations with food intake, metabolism, exercise capacity, and hormones,” Cancer, vol. 103, no. 10, pp. 2189–2198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. M. Ibrahim, “Subcutaneous and visceral adipose tissue: structural and functional differences,” Obesity Reviews, vol. 11, no. 1, pp. 11–18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Trayhurn and I. S. Wood, “Adipokines: inflammation and the pleiotropic role of white adipose tissue,” British Journal of Nutrition, vol. 92, no. 3, pp. 347–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Ronti, G. Lupattelli, and E. Mannarino, “The endocrine function of adipose tissue: an update,” Clinical Endocrinology, vol. 64, no. 4, pp. 355–365, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. T. H. Mayi, M. Daoudi, B. Derudas et al., “Human adipose tissue macrophages display activation of cancer-related pathways,” The Journal of Biological Chemistry, vol. 287, no. 26, pp. 21904–21913, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Bing, “Lipid mobilization in cachexia: mechanisms and mediators,” Current Opinion in Supportive and Palliative Care, vol. 5, no. 4, pp. 356–360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. L. Batista, S. B. Peres, M. E. McDonald et al., “Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors,” Cytokine, vol. 57, no. 1, pp. 9–16, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Strimbu and J. A. Tavel, “What are biomarkers?” Current Opinion in HIV and AIDS, vol. 5, no. 6, pp. 463–466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Dictionary of Cancer Terms, National Cancer Institute, http://www.Cancer.gov/dictionary/?searchTxt=biomarker.
  17. J. D. Brooks, “Translational genomics: the challenge of developing cancer biomarkers,” Genome Research, vol. 22, no. 2, pp. 183–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. C. O. Madu and Y. Lu, “Novel diagnostic biomarkers for prostate cancer,” Journal of Cancer, vol. 1, no. 1, pp. 150–177, 2010. View at Google Scholar · View at Scopus
  19. E. Drucker and K. Krapfenbauer, “Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine,” EPMA Journal, vol. 4, no. 1, article 7, 2013. View at Publisher · View at Google Scholar
  20. C. N. A. M. Oldenhuis, S. F. Oosting, J. A. Gietema, and E. G. E. de Vries, “Prognostic versus predictive value of biomarkers in oncology,” European Journal of Cancer, vol. 44, no. 7, pp. 946–953, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. K. C. H. Fearon, D. J. Glass, and D. C. Guttridge, “Cancer cachexia: mediators, signaling, and metabolic pathways,” Cell Metabolism, vol. 16, no. 2, pp. 153–166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Cabassi and S. Tedeschi, “Zinc-α2-glycoprotein as a marker of fat catabolism in humans,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 16, no. 3, pp. 267–271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. J. Garcia-Oria Serrano, M. Armengol Carrasco, A. Caballero Millán, C. D. Ching, and A. Codina Cazador, “Is Body Mass Index a prognostic factor of survival in colonic cancer? A multivariate analysis,” Cirugia Espanola, vol. 89, no. 3, pp. 152–158, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. E. D. Fabbro, V. Baracos, W. Demark-Wahnefried, T. Bowling, J. Hopkinson, and E. Bruera, Eds., Nutrition and the Cancer Patient, Oxford University Press, New York, NY, USA, 2010.
  25. C. M. Prado, M. B. Sawyer, S. Ghosh et al., “Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?” American Journal of Clinical Nutrition, vol. 98, no. 4, pp. 1012–1019, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. R. Lieffers, M. Mourtzakis, K. D. Hall, L. J. McCargar, C. M. M. Prado, and V. E. Baracos, “A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands,” American Journal of Clinical Nutrition, vol. 89, no. 4, pp. 1173–1179, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. B. H. L. Tan, D. A. C. Deans, R. J. E. Skipworth, J. A. Ross, and K. C. H. Fearon, “Biomarkers for cancer cachexia: is there also a genetic component to cachexia?” Supportive Care in Cancer, vol. 16, no. 3, pp. 229–234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Kawakami, T. Murase, H. Ogawa et al., “Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells,” Journal of Biochemistry, vol. 101, no. 2, pp. 331–338, 1987. View at Google Scholar · View at Scopus
  29. S. W. Coppack, “Pro-inflammatory cytokines and adipose tissue,” Proceedings of the Nutrition Society, vol. 60, no. 3, pp. 349–356, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. X. Yang, X. Zhang, B. L. Heckmann, X. Lu, and J. Liu, “Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor-α (TNF-α)-induced lipolysis in adipocytes,” The Journal of Biological Chemistry, vol. 286, no. 47, pp. 40477–40485, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Van Hall, A. Steensberg, M. Sacchetti et al., “Interleukin-6 stimulates lipolysis and fat oxidation in humans,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 7, pp. 3005–3010, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Beutler, D. Greenwald, J. D. Hulmes et al., “Identity of tumour necrosis factor and the macrophage-secreted factor cachectin,” Nature, vol. 316, no. 6028, pp. 552–554, 1985. View at Publisher · View at Google Scholar · View at Scopus
  33. W. P. Cawthorn and J. K. Sethi, “TNF-α and adipocyte biology,” FEBS Letters, vol. 582, no. 1, pp. 117–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. A. J. Karayiannakis, K. N. Syrigos, A. Polychronidis, M. Pitiakoudis, A. Bounovas, and K. Simopoulos, “Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients,” Anticancer Research, vol. 21, no. 2, pp. 1355–1358, 2001. View at Google Scholar · View at Scopus
  35. S. K. Das, S. Eder, S. Schauer et al., “Adipose triglyceride lipase contributes to cancer-associated cachexia,” Science, vol. 333, no. 6039, pp. 233–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. K. Das and G. Hoefler, “The role of triglyceride lipases in cancer associated cachexia,” Trends in Molecular Medicine, vol. 19, no. 5, pp. 292–301, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Hosono, E. Yamada, H. Endo et al., “Increased tumor necrosis factor receptor 1 expression in human colorectal adenomas,” World Journal of Gastroenterology, vol. 18, no. 38, pp. 5360–5368, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Blum, A. Omlin, V. E. Baracos et al., “Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer,” Critical Reviews in Oncology/Hematology, vol. 80, no. 1, pp. 114–144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. J. Staal-Van den Brekel, M. A. Dentener, A. M. W. J. Schols, W. A. Buurman, and E. F. M. Wouters, “Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients,” Journal of Clinical Oncology, vol. 13, no. 10, pp. 2600–2605, 1995. View at Google Scholar · View at Scopus
  40. M. Tsoli, M. Schweiger, A. S. Vanniasinghe et al., “Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation,” PLoS ONE, vol. 9, no. 3, Article ID e92966, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. M. L. Batista Jr., M. Olivan, P. S. M. Alcantara et al., “Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients,” Cytokine, vol. 61, no. 2, pp. 532–539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. J. Tisdale, “Mechanisms of cancer cachexia,” Physiological Reviews, vol. 89, no. 2, pp. 381–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Scheede-Bergdahl, H. L. Watt, B. Trutschnigg et al., “Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?” Clinical Nutrition, vol. 31, no. 1, pp. 85–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Iwase, T. Murakami, Y. Saito, and K. Nakagawa, “Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients,” European Cytokine Network, vol. 15, no. 4, pp. 312–316, 2004. View at Google Scholar · View at Scopus
  45. M. Maltoni, L. Fabbri, O. Nanni et al., “Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients,” Supportive Care in Cancer, vol. 5, no. 2, pp. 130–135, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Petruzzelli, M. Schweiger, R. Schreiber et al., “A switch from white to brown fat increases energy expenditure in cancer-associated cachexia,” Cell Metabolism, vol. 20, no. 3, pp. 433–447, 2014. View at Publisher · View at Google Scholar
  47. M. J. Tisdale, “Molecular pathways leading to cancer cachexia,” Physiology, vol. 20, no. 5, pp. 340–348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. J. M. Argilés, F. J. López-Soriano, and S. Busquets, “Counteracting inflammation: a promising therapy in cachexia,” Critical Reviews in Oncogenesis, vol. 17, no. 3, pp. 253–262, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Fantuzzi, “Adipose tissue, adipokines, and inflammation,” Journal of Allergy and Clinical Immunology, vol. 115, no. 5, pp. 911–920, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. M. A. Cowley, J. L. Smart, M. Rubinstein et al., “Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus,” Nature, vol. 411, no. 6836, pp. 480–484, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. T. L. Horvath, F. Naftolin, S. P. Kalra, and C. Leranth, “Neuropeptide-Y innervation of beta-endorphin-containing cells in the rat mediobasal hypothalamus: A light and electron microscopic double immunostaining analysis,” Endocrinology, vol. 131, no. 5, pp. 2461–2467, 1992. View at Publisher · View at Google Scholar · View at Scopus
  52. N. R. Shah and E. R. Braverman, “Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin,” PLoS ONE, vol. 7, no. 4, Article ID e33308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. W. T. Chance, A. Balasubramaniam, J. E. Fischer, E. M. Copeland III, R. S. Jones, and K. I. Bland, “Neuropeptide Y and the development of cancer anorexia,” Annals of Surgery, vol. 221, no. 5, pp. 579–589, 1995. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Bulló, P. García-Lorda, I. Megias, and J. Salas-Salvadó, “Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression,” Obesity Research, vol. 11, no. 4, pp. 525–531, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. C. D. Russell, M. R. Ricci, R. E. Brolin, E. Magill, and S. K. Fried, “Regulation of the leptin content of obese human adipose tissue,” American Journal of Physiology—Endocrinology and Metabolism, vol. 280, no. 3, pp. E399–E404, 2001. View at Google Scholar · View at Scopus
  56. R. V. Considine, M. K. Sinha, M. L. Heiman et al., “Serum immunoreactive-leptin concentrations in normal-weight and obese humans,” The New England Journal of Medicine, vol. 334, no. 5, pp. 292–295, 1996. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Shimizu, Y. Shimomura, R. Hayashi et al., “Serum leptin concentration is associated with total body fat mass, but not abdominal fat distribution,” International Journal of Obesity, vol. 21, no. 7, pp. 536–541, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. C. E. Ruhl, T. B. Harris, J. Ding et al., “Body mass index and serum leptin concentration independently estimate percentage body fat in older adults,” The American Journal of Clinical Nutrition, vol. 85, no. 4, pp. 1121–1126, 2007. View at Google Scholar · View at Scopus
  59. A. Kowalczuk, A. Wiecek, E. Franek, and F. Kokot, “Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy,” Polskie Archiwum Medycyny Wewnetrznej, vol. 106, no. 2, pp. 657–668, 2001. View at Google Scholar · View at Scopus
  60. B. Weryńska, M. Kosacka, M. Gołecki, and R. Jankowska, “Leptin serum levels in cachectic and non-cachectic lung cancer patients,” Pneumonologia i Alergologia Polska, vol. 77, no. 6, pp. 500–505, 2009. View at Google Scholar · View at Scopus
  61. J. Smiechowska, A. Utech, G. Taffet, T. Hayes, M. Marcelli, and J. M. Garcia, “Adipokines in patients with cancer anorexia and cachexia,” Journal of Investigative Medicine, vol. 58, no. 3, pp. 554–559, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Dülger, S. Alici, M. R. Şekeroǧlu et al., “Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer,” International Journal of Clinical Practice, vol. 58, no. 6, pp. 545–549, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. A. M. Wallace, N. Sattar, and D. C. McMillan, “Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients,” Clinical Cancer Research, vol. 4, no. 12, pp. 2977–2979, 1998. View at Google Scholar · View at Scopus
  64. G. Mantovani, A. Macciò, L. Mura et al., “Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites,” Journal of Molecular Medicine, vol. 78, no. 10, pp. 554–561, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. A. G. W. Moses, N. Dowidar, B. Holloway, I. Waddell, K. C. H. Fearon, and J. A. Ross, “Leptin and its relation to weight loss, ob gene expression and the acute-phase response in surgical patients,” British Journal of Surgery, vol. 88, no. 4, pp. 588–593, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. A. M. Wallace, A. Kelly, N. Sattar, C. S. McArdle, and D. C. McMillan, “Circulating concentrations of ‘free’ leptin in relation to fat mass and appetite in gastrointestinal cancer patients,” Nutrition and Cancer, vol. 44, no. 2, pp. 156–160, 2002. View at Google Scholar · View at Scopus
  67. M. R. Alemán, F. Santolaria, N. Batista et al., “Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition?” Cytokine, vol. 19, no. 1, pp. 21–26, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Diakowska, M. Krzystek-Korpacka, K. Markocka-Maczka, W. Diakowski, M. Matusiewicz, and K. Grabowski, “Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract,” Cytokine, vol. 51, no. 2, pp. 132–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. Q. Huang, X. Zhang, Z.-W. Jiang, B.-Z. Liu, N. Li, and J.-S. Li, “Hypoleptinemia in gastric cancer patients: relation to body fat mass, insulin, and growth hormone,” Journal of Parenteral and Enteral Nutrition, vol. 29, no. 4, pp. 229–235, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Tessitore, B. Vizio, D. Pesola et al., “Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients,” International Journal of Oncology, vol. 24, no. 6, pp. 1529–1535, 2004. View at Google Scholar · View at Scopus
  71. T. Koester-Weber, J. Valtueña, C. Breidenassel et al., “Reference values for leptin, cortisol, insulin and glucose, among European adolescents and their association with adiposity: the HELENA study,” Nutrición Hospitalaria, vol. 30, no. 5, pp. 1181–1190, 2014. View at Publisher · View at Google Scholar
  72. I. Dahlman, N. Mejhert, K. Linder et al., “Adipose tissue pathways involved in weight loss of cancer cachexia,” British Journal of Cancer, vol. 102, no. 10, pp. 1541–1548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. D.-X. Cao, G.-H. Wu, Z.-A. Yang et al., “Role of β1-adrenoceptor in increased lipolysis in cancer cachexia,” Cancer Science, vol. 101, no. 7, pp. 1639–1645, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. S. D. Zuijdgeest-Van Leeuwen, J. W. O. Van Den Berg, J. L. D. Wattimena et al., “Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects,” Metabolism: Clinical and Experimental, vol. 49, no. 7, pp. 931–936, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Klein and R. R. Wolfe, “Whole-body lipolysis and triglyceride-fatty acid cycling in cachectic patients with esophageal cancer,” Journal of Clinical Investigation, vol. 86, no. 5, pp. 1403–1408, 1990. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Agustsson, P. Wikrantz, M. Rydén, T. Brismar, and B. Isaksson, “Adipose tissue volume is decreased in recently diagnosed cancer patients with cachexia,” Nutrition, vol. 28, no. 9, pp. 851–855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Rydén, T. Agustsson, J. Andersson, J. Bolinder, E. Toft, and P. Arner, “Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states,” Journal of Internal Medicine, vol. 271, no. 4, pp. 414–420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Jeevanandam, G. D. Horowitz, S. F. Lowry, and M. F. Brennan, “Cancer cachexia and the rate of whole body lipolysis in man,” Metabolism, vol. 35, no. 4, pp. 304–310, 1986. View at Publisher · View at Google Scholar · View at Scopus
  79. J. F. Horowitz, “Fatty acid mobilization from adipose tissue during exercise,” Trends in Endocrinology and Metabolism, vol. 14, no. 8, pp. 386–392, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. E. C. Lin, “Glycerol utilization and its regulation in mammals,” Annual Review of Biochemistry, vol. 46, pp. 765–795, 1977. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Maeda, T. Funahashi, and I. Shimomura, “Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9,” Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 11, pp. 627–634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. W. Burgi and K. Schmid, “Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma,” The Journal of Biological Chemistry, vol. 236, pp. 1066–1074, 1961. View at Google Scholar · View at Scopus
  83. I. Díez-Itza, L. M. Sánchez, M. T. Allende, F. Vizoso, A. Ruibal, and C. López-Otín, “Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters,” European Journal of Cancer, vol. 29, no. 9, pp. 1256–1260, 1993. View at Publisher · View at Google Scholar · View at Scopus
  84. L. P. Hale, D. T. Price, L. M. Sanchez, W. Demark-Wahnefried, and J. F. Madden, “Zinc α-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer,” Clinical Cancer Research, vol. 7, no. 4, pp. 846–853, 2001. View at Google Scholar · View at Scopus
  85. D. L. Albertus, C. W. Seder, G. Chen et al., “AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma,” Journal of Thoracic Oncology, vol. 3, no. 11, pp. 1236–1244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Felix, F. Fakelman, D. Hartmann et al., “Identification of serum proteins involved in pancreatic cancer cachexia,” Life Sciences, vol. 88, no. 5-6, pp. 218–225, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. Bao, C. Bing, L. Hunter, J. R. Jenkins, M. Wabitsch, and P. Trayhurn, “Zinc-α 2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes,” FEBS Letters, vol. 579, no. 1, pp. 41–47, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. C. Bing, Y. Bao, J. Jenkins et al., “Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 8, pp. 2500–2505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. S. T. Russell, T. P. Zimmerman, B. A. Domin, and M. J. Tisdale, “Induction of lipolysis in vitro and loss of body fat in vivo by zinc-α2-glycoprotein,” Biochimica et Biophysica Acta, vol. 1636, no. 1, pp. 59–68, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. S. T. Russell and M. J. Tisdale, “Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 72, no. 6, pp. 409–414, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. S. T. Russell, K. Hirai, and M. J. Tisdale, “Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor,” British Journal of Cancer, vol. 86, no. 3, pp. 424–428, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. T. Mracek, N. A. Stephens, D. Gao et al., “Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients,” British Journal of Cancer, vol. 104, no. 3, pp. 441–447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. F.-Y. Gong, J.-Y. Deng, H.-J. Zhu, H. Pan, L.-J. Wang, and H.-B. Yang, “Fatty acid synthase and hormone-sensitive lipase expression in liver are involved in zinc-α2-glycoprotein-induced body fat loss in obese mice,” Chinese Medical Sciences Journal, vol. 25, no. 3, pp. 169–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. S. T. Russell and M. J. Tisdale, “The role of glucocorticoids in the induction of zinc-α2- glycoprotein expression in adipose tissue in cancer cachexia,” British Journal of Cancer, vol. 92, no. 5, pp. 876–881, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. M. L. Knapp, S. Al-Sheibani, P. G. Riches, I. W. F. Hanham, and R. H. Phillips, “Hormonal factors associated with weight loss in patients with advanced breast cancer,” Annals of Clinical Biochemistry, vol. 28, no. 5, pp. 480–486, 1991. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Bing, T. Mracek, D. Gao, and P. Trayhurn, “Zinc-α2-glycoprotein: an adipokine modulator of body fat mass,” International Journal of Obesity, vol. 34, no. 11, pp. 1559–1565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. D. C. Y. Yeung, K. S. L. Lam, Y. Wang, A. W. K. Tso, and A. Xu, “Serum zinc-alpha2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2531–2536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. D. M. Selva, A. Lecube, C. Hernández, J. A. Baena, J. M. Fort, and R. Simó, “Lower zinc-α2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 11, pp. 4499–4507, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. Y. J. Kim, K. Sertamo, M. A. Pierrard et al., “Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach,” Journal of Proteome Research, vol. 14, no. 3, pp. 1412–1419, 2015. View at Publisher · View at Google Scholar
  100. M. Gosho, K. Nagashima, and Y. Sato, “Study designs and statistical analyses for biomarker research,” Sensors, vol. 12, no. 7, pp. 8966–8986, 2012. View at Publisher · View at Google Scholar · View at Scopus